A new UK-based company has been launched to explore the dark matter of the genome with the goal of identifying antigens for the development of off-the-shelf cancer vaccines and T cell receptor based immunotherapies. Ervaxx Ltd was founded on original research by scientists at the Francis Crick Institute in London and launched on 6 November with $17.5 million in seed and Series A funding from SV Health Investors and an undisclosed global pharmaceutical company.
